Galectin Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Galectin Therapeutics Inc 's ROA in the second quarter of 2026?
Galectin Therapeutics Inc recorded a cumulative net loss of $-28 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -176.86%.

However, within the Healthcare sector 834 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4425, from total ROA ranking in the first quarter of 2026 at 5207.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-4.94 %	65.4 %	11.55 %	-55.6 %	-43.58 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-28	-26	-31	-37	-40
Return On Assets (TTM)	-176.86 %	-164.73 %	-214.11 %	-268.52 %	-225.08 %
GALT's Total Ranking	# 4425	# 5207	# 4672	# 4705	# 4762
Total Assets (TTM) in million	15	16	20	13	16
Seq. Total Assets Change	-5.88 %	-19.25 %	51.7 %	-17.54 %	63.75 %
Seq. Net Income Change	-	-	-	-	-

GALT's 5 Years Annual ROA >> Back to GALT Management Effectiveness >> Compare GALT ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 396
Sector	# 835
Overall	# 4405

Return On Assets Statistics
High	Average	Low
-29.46 %	-136.36 %	-268.52 %
(Mar 31 2020)		(Sep 30 2025)

Financial Statements
Galectin Therapeutics Inc 's Assets	$ 15 million	GALT's Balance sheet
Galectin Therapeutics Inc 's Income	$ -9 million	Quarterly GALT's Income Statement
GALT's Income by Division		See GALT's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	11.55 %	-37.96 %	32.49 %	-49.11 %	41.31 %
Total Assets in million	20	17	28	21	42
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-31	-47	-45	-39	-31
Annual Return On Assets	-158 %	-268.92 %	-158.46 %	-182.18 %	-72.98 %

GALT's 5 Years Annual ROA >> Back to GALT Management Effectiveness >> Compare GALT ROA to its Competitors

More Return On Assets Ratios
GALT's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
GALT's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for GALT's Competitors
Subscribers only: Roa for Galectin Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for GALT's Customers

You may also want to know
GALT's Roi	GALT's Inventory Turnover Ratio	GALT's Growth Rates	GALT's Dividend Comparisons
	GALT's Profitability Ratios	GALT's Asset Turnover Ratio	GALT's Dividend Growth
GALT's Roe	GALT's Valuation Ratios	GALT's Financial Strength Ratios	GALT's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:08:33+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.